PLTR
Palantir
-- 76.070 TSLA
Tesla
-- 436.230 NVDA
NVIDIA
-- 134.250 MSTR
MicroStrategy
-- 408.670 AVGO
Broadcom
-- 224.800 
$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces ...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 patients required dose reduction
One patient experienced Grade 4 gamma-glutamyl transferase elevation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment